Literatur
Parving HH, Brenner BM, McMurray JJV et al (2012) Cardiorenal end points in a trial of Aliskiren for type 2 diabetes. N Engl J Med [Epub ahead of print]
Torres VE, Chapman AB, Devuyst O et al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med [Epub ahead of print]
The EVOLVE Trial Investigators; Chertow GM, Block GA, Correa-Rotter R et al (2012) Effect of Cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med [Epub ahead of print]
Jones RB, Walsh M (2012) A randomized trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA-associated vasculitis: MYCYC – On behalf of the European Vasculitis Study Group. ASN-Kongress
Herzog CA, Solid C (2012) Survival of patients in the US after surgical versus percutaneous coronary intervention. ASN-Kongress
Chandran S, Masharani U, Webber AB, Wojciechowski D (2012) Ten-year safety of prediabetic living kidney donors. ASN-Kongress
Interessenkonflikt
Der korrespondierende Autor weist auf folgende Beziehungen hin: Beratertätigkeit für die Firmen Abbott, Amgen und Vifor sowie Mitgliedschaft im Executive Committee der EVOLVE-Studie.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Floege, J. Kidney Week 2012. Nephrologe 8, 77–78 (2013). https://doi.org/10.1007/s11560-012-0716-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11560-012-0716-x